OMEICOS Therapeutics is a clinical stage biopharmaceutical company focused on developing a novel class of synthetic bioactive lipid mediators for the treatment of cardiovascular, ophthalmic and other chronic inflammatory diseases. OMEICOS’ compounds activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available but can be used in other application routes as well. OMEICOS has the exclusive, worldwide license for IP rights from Max Delbrueck Center for Molecular Medicine in Berlin, Germany, and UT Southwestern, Texas, USA, to develop its lead compound OMT-28 and has established a comprehensive pipeline of discovery and pre-clinical stage compounds. OMEICOS is financed by a strong consortium of private and public VC investors and its research activities are supported by a grant from the German Ministry of Education and Research (BMBF).
Location: Germany, Berlin
Total raised: $37.45M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | High-Tech ... | htgf.de |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 21.06.2023 | Grant | $2.73M | - |
| 02.11.2018 | Series C | $19.36M | Forbion |
| 01.03.2017 | Series B | $8.74M | - |
| 15.04.2015 | Series A | $6.62M | - |
Mentions in press and media 14
| Date | Title | Description | Source |
| 21.06.2023 | OMEICOS Therapeutics Receives 2.5 million Euros in Grant Fun... | BERLIN, GERMANY, June 21, 2023 – OMEICOS, a biopharmaceutical company developing first-in-class smal... | forbion.co... |
| 09.10.2021 | Top 10 Healthcare Startups in Germany | The global healthcare market is expected to reach USD 11,908.9 billion by 2022, growing at a CAGR of... | vcbay.news... |
| 05.11.2018 | Term Sheet — Monday, November 5 | MASA WATCH 2018 Good morning, Term Sheet readers. Paid Content What you need to know about growing... | fortune.co... |
| 02.11.2018 | Omeicos scores $19.5M in Series C to take its omega-3 drug... | Berlin-based Omeicos Therapeutics has closed €17 million in Series C financing, money the c... | endpts.com... |
| 02.11.2018 | Berlin-based OMEICOS Therapeutics has raised €17 million to ... | Berlin-based OMEICOS Therapeutics, a biopharmaceutical company that specializes in preventing and tr... | eu-startup... |
| 02.11.2018 | Omeicos raises €17M to run phase 2 atrial fibrillation trial... | Omeicos Therapeutics has raised €17 million ($19 million) to develop an atrial fibrillation candidat... | fiercebiot... |
| 02.11.2018 | Omeicos raises €17M to run phase 2 atrial fibrillation trial... | Omeicos Therapeutics has raised €17 million ($19 million) to develop an atrial fibrillation candidat... | fiercebiot... |
| 02.11.2018 | Omeicos Therapeutics Raises €17M in Series C Financing | Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company, raised €17m in Series C fin... | finsmes.co... |
| 02.11.2018 | Top tech startup news stories you need to know this Friday, ... | Good morning! Here are some of the top tech startup news stories for today, Friday, November 2. Exp... | techstartu... |
| 02.11.2018 | Forbion Leads €17m Series C Financing of OMEICOS Therapeutic... | Forbion invests €12.5m from its recently launched Forbion IV fund OMEICOS is pioneering the develop... | forbion.co... |
Show more